Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer
Y.-L. Zhang, Z.-L. Zhang, X.-B. Zhu, L. Xu, P. Lu, M. Xu, W.-J. Liu, X.-Y. Zhang, H.-M. Yao, X.-W. Ye Department of Respiratory Medicine, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, P.R. China. gzphyaohongmei@163.com
OBJECTIVE: Circulating microRNAs (miRNAs) are promising biomarkers for the diagnosis and prognosis prediction of cancer. In the study, we aimed to investigate the potential clinical significance of the plasma miR-25 in non-small cell lung carcinoma (NSCLC).
PATIENTS AND METHODS: We first compared the miRNAs expression pattern between NSCLC tissues and adjacent normal tissues then, bioinformatic analysis of the downstream targets of miR-25 was performed. The diagnostic and prognostic value of the plasma miR-25 in NSCLC was then evaluated.
RESULTS: The expression level of miR-25 was increased in NSCLC tissues compared to the adjacent normal tissues. In addition, bioinformatic analysis of the downstream-targeted genes of miR-25 revealed that many gene ontology functions and pathways were associated with cancer progression. The levels of plasma miR-25 were significantly upregulated in NSCLC patients compared to normal controls. In addition, the plasma miR-25 levels were especially higher in NSCLC patients with positive lymph node metastasis, poorly differentiation or advanced clinical stage. Subsequently, we found that the plasma miR-25 expression levels were dramatically decreased in 45 NSCLC patients after receiving surgical treatment. The receiver operating characteristic (ROC) curve analysis indicated that the plasma miR-25 exhibited high diagnostic sensitivity and specificity to discriminate NSCLC cases from healthy subjects. More interestingly, the combination of the plasma miR-25 and carcinoembryonic antigen (CEA) could effectively enhance the accuracy for distinguishing NSCLC patients from normal controls. Moreover, the plasma miR-25 overexpression was closely correlated with aggressive clinical characteristics and poor survival. Finally, the plasma miR-25 was identified as an independent prognostic marker for the overall survival of NSCLC.
CONCLUSIONS: Collectively, our findings demonstrated that the plasma miR-25 might serve as a novel promising biomarker in the diagnosis and prognosis prediction of NSCLC.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Y.-L. Zhang, Z.-L. Zhang, X.-B. Zhu, L. Xu, P. Lu, M. Xu, W.-J. Liu, X.-Y. Zhang, H.-M. Yao, X.-W. Ye
Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer
Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 12
Pages: 5251-5259
DOI: 10.26355/eurrev_201906_18191